Etoricoxib is a next-generation, highly selective cyclooxygenase-2 (COX-2) inhibitor that provides targeted anti-inflammatory effects. It acts specifically on the inducible COX-2 isoforms responsible for inflammatory prostaglandin synthesis at injury sites, while completely sparing the constitutive COX-1 pathways that protect the stomach lining and blood platelets. This selective mechanism delivers high-strength pain relief and anti-swelling benefits with a significantly lower risk of gastrointestinal ulcers.